COMPASS BIOTECHNOLOGIES ANNOUNCES MEMORANDUM OF UNDERSTANDING WITH PANGEN BIOTECH INC.

EDMONTON, April 11 /PRNewswire/ - Compass Biotechnologies, Inc. (Compass) (formerly Cyplasin Biomedical Ltd) is newly focused on the development and commercialization of generic, biosimiliar and bio-better products.  Generic drugs are chemical copies of existing drugs and biosimiliars are protein based drugs that do a similar job to the original protein based product. Bio-Better products are new versions of patent-expired biologically based drugs that do the job smarter, more economically, or with a better side-effect profile. A "bio-better" is a biopharmaceutical product that is a copy of an existing product but is designed to have superior efficacy, safety, or improved drug delivery characteristics compared to the original product.

As part of this new strategy and focus Compass is pleased to announce the signing of a Memorandum of Understanding (MOU) with PanGen Biotech Inc., (PanGen) of South Korea.  The terms of the MOU lay down the foundation for a definitive agreement to be signed within the next 60 days between the Parties, whereby PanGen will manufacture under cGMP conditions, major active pharmaceutical ingredients (API's) which will be used to produce the bio better versions of various drug products. As PanGen's expertise lies with production of proteins and antibodies, Compass will be supplied with API's to produce Bio-Better drugs which may encompass such block buster products as EPO, G-CSF, beta-IFN, alpha interferon and Factor VIII products. The terms of the MOU give Compass rights to North, Central and South America as well as the EU countries and other geographical areas.

Worldwide, biological based drugs generate more than US$120 billion in revenue. From monoclonal antibody therapies and cytokine growth factors to vaccines and blood factors, biopharmaceuticals have a healthy and expanding bottom-line. As more and more of the first-generation biological such as recombinant human versions of insulin, growth hormone, erythropoietin (EPO) become patent-expired, they are thrown into competition with "biosimilars" - generic versions of the biotech drug. The impact on the industry is undeniable: The rising cost of existing and expensive biopharmaceuticals contrasted with needed lower market price points have created the need for increasing availability of generic and biosimilars.

However Garth Likes CEO of Compass says" while our strategy is to look at generic and biosimiliar opportunities; we do not wish to be strictly a generic drug me too company.  What we have done with the signing of this MOU with PanGen is to secure the supply of cGMP produced protein APIs which will allow us to add our own value, so as to create Bio-Better products and which where possible will also have  their own patent protection.

Joseph Sinkule Director of Compass agrees and states "the first-generation biologicals are all immediate-release and are eliminated rapidly from the blood.  They are usually injected by syringe either subcutaneously or via an intravenous infusion. Bio-Betters make existing biologic drugs even better by for example formulating the protein with patented polyethylene glycol (PEG) or other carriers to make the new biological drug more efficacious, or remaining in the blood longer allowing for less frequent dosing, and most critically potentially reducing the risk of immunogenicity (side effects and allergic reactions) to the protein. We have multiple strategies in play which will allow us to announce future products which will lead to nearer term revenue generation for the Company." Mr. Likes confirmed the signing of this MOU opens the door for many multiple millions in revenues for the Company and expects to announce the signing of the definitive agreement shortly.

About Compass Biotechnologies

Compass Biotechnologies (COBI: OB) is an Edmonton based biotechnology product development company focused on generic, biosimiliar and biobetter products. From a development perspective, these types of products have lower development costs and lower development risk due to well established mechanisms of action, a known safety profile, with broad clinical indications for physician use. Comparability testing in preclinical and clinical trials will be needed to show the added benefits of the biosimiliar and bio-better drug product.

About PanGen Bio:

PanGen is a leading biotechnology company based in South Korea with e3xpertise in developing animal cell lines (particularly Chinese Hamster Ovary cells) and in production of proteins or antibodies from those cells.   PanGen has developed novel CHO cell expression systems that confer the overall efficiency of manipulation to cut down the conventional time and costs to handle the recombinant gene expression in animal cells.  The combination of the patent pending technologies and well-trained researchers has made PanGen one of the leading companies in CHO cell technology.

About C-Pharma

Compass has also created a private wholly owned subsidiary company called C- Pharma Inc. This Company through its parent Compass; is charged with the creation of a Hepatitis product development franchise.  C-Pharma has acquired the rights to novel vaccine technology which is currently being developed for Hepatitis C applications. This technology was previously developed at the National Institutes of Health (NIH) and licensed to the Company on a worldwide exclusive basis.  In addition C-Pharma is developing its own generics for two drugs known as Ribavirin and pegylated alpha interferon.  These two drugs are currently the drugs used for patients who are chronically infected with the Hepatitis C virus and in combination are the current standard of care.  These two drugs when used together for Hepatitis C chronic infection create a market of $2 billion a year worldwide.

Forward Looking Statements

This news release contains "forward-looking statements", as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Statements in this current report which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. 

Actual results could differ from those projected in any forward-looking statements due to numerous factors.  Such factors include, among others, the inherent uncertainty of financial estimates and projections, the competitive and regulatory environments, stock market conditions, unforeseen technical difficulties and our ongoing ability to operate a business and obtain financing.  These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. 

Although we believe that our beliefs, plans, expectations and intentions contained in this current report are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate.  Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our quarterly reports on Form 10-Q and our other periodic reports filed from time-to-time with the Securities and Exchange Commission pursuant to the Securities Exchange Act.

SOURCE COMPASS BIOTECHNOLOGIES INC.